
## Melissa A Rolfes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2626170/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Influenza Testing Practices in Hospitalized Children at United States Medical Centers, 2015-2018. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 5-8.	0.6	2
2	Incidence Rates, Household Infection Risk, and Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and New York City, New York. JAMA Pediatrics, 2022, 176, 59.	3.3	92
3	Household Transmission and Clinical Features of SARS-CoV-2 Infections. Pediatrics, 2022, 149, .	1.0	20
4	mRNA COVIDâ€19 vaccine effectiveness against SARSâ€CoVâ€2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021. Influenza and Other Respiratory Viruses, 2022, 16, 607-612.	1.5	7
5	Rates of Severe Influenza-Associated Outcomes Among Older Adults Living With Diabetes—Influenza Hospitalization Surveillance Network (FluSurv-NET), 2012–2017. Open Forum Infectious Diseases, 2022, 9, ofac131.	0.4	10
6	Epidemiology, Clinical Characteristics, and Outcomes of Influenza-Associated Hospitalizations in US Children Over 9 Seasons Following the 2009 H1N1 Pandemic. Clinical Infectious Diseases, 2022, 75, 1930-1939.	2.9	17
7	SARS-CoV-2 Virus Dynamics in Recently Infected People—Data From a Household Transmission Study. Journal of Infectious Diseases, 2022, 226, 1699-1703.	1.9	2
8	Relative and Absolute Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults—United States, 2015–2017. Clinical Infectious Diseases, 2021, 72, 995-1003.	2.9	29
9	Influenza-Associated Medical Visits Prevented by Influenza Vaccination in Young Children in Thailand, 2012–2014. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 349-351.	0.6	0
10	Implications of Shortened Quarantine Among Household Contacts of Index Patients with Confirmed SARS-CoV-2 Infection — Tennessee and Wisconsin, April–September 2020. Morbidity and Mortality Weekly Report, 2021, 69, 1633-1637.	9.0	16
11	Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults. Annals of Internal Medicine, 2021, 174, 583-584.	2.0	6
12	Estimating the number of averted illnesses and deaths as a result of vaccination against an influenza pandemic in nine low- and middle-income countries. Vaccine, 2021, 39, 4219-4230.	1.7	1
13	Performance of Self-Collected Anterior Nasal Swabs and Saliva Specimens for Detection of SARS-CoV-2 During Symptomatic and Asymptomatic Periods. Open Forum Infectious Diseases, 2021, 8, ofab484.	0.4	2
14	Differentiating severe and non-severe lower respiratory tract illness in patients hospitalized with influenza: Development of the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale. PLoS ONE, 2021, 16, e0258482.	1.1	2
15	Reply to Gonzales-Luna and Carlson. Clinical Infectious Diseases, 2020, 70, 357-358.	2.9	0
16	Projected Population Benefit of Increased Effectiveness and Coverage of Influenza Vaccination on Influenza Burden in the United States. Clinical Infectious Diseases, 2020, 70, 2496-2502.	2.9	45
17	Effects of Influenza Vaccination in the United States During the 2018–2019 Influenza Season. Clinical Infectious Diseases, 2020, 71, e368-e376.	2.9	72
18	Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza vaccines in children – A systematic review and a meta-analysis. Vaccine, 2020, 38, 608-619.	1.7	13

MELISSA A ROLFES

#	Article	IF	CITATIONS
19	Vaccine Effectiveness Against Influenza-Associated Lower Respiratory Tract Infections in Hospitalized Adults, Louisville, Kentucky, 2010–2013. Open Forum Infectious Diseases, 2020, 7, ofaa262.	0.4	9
20	Investigation and Serologic Follow-Up of Contacts of an Early Confirmed Case-Patient with COVID-19, Washington, USA. Emerging Infectious Diseases, 2020, 26, 1671-1678.	2.0	7
21	Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults. Annals of Internal Medicine, 2020, 173, 605-613.	2.0	81
22	Variability in published rates of influenza-associated hospitalizations: A systematic review, 2007-2018. Journal of Global Health, 2020, 10, 020430.	1.2	13
23	Severe Acute Respiratory Syndrome Coronavirus 2 Prevalence, Seroprevalence, and Exposure among Evacuees from Wuhan, China, 2020. Emerging Infectious Diseases, 2020, 26, 1998-2004.	2.0	5
24	Impact of community engagement and social support on the outcomes of HIV-related meningitis clinical trials in a resource-limited setting. Research Involvement and Engagement, 2020, 6, 49.	1.1	3
25	Enhanced contact investigations for nine early travel-related cases of SARS-CoV-2 in the United States. PLoS ONE, 2020, 15, e0238342.	1.1	22
26	First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet, The, 2020, 395, 1137-1144.	6.3	435
27	Update on Rolfes et al, "Effects of Influenza Vaccination in the United States During the 2017–2018 Influenza Seasonâ€: Clinical Infectious Diseases, 2020, 71, 1585-1586.	2.9	10
28	Early season pediatric influenza B/Victoria virus infections associated with a recently emerged virus subclade — Louisiana, 2019. American Journal of Transplantation, 2020, 20, 606-609.	2.6	1
29	Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak — United States, December 31, 2019–February 4, 2020. American Journal of Transplantation, 2020, 20, 889-895.	2.6	46
30	Respiratory and Nonrespiratory Diagnoses Associated With Influenza in Hospitalized Adults. JAMA Network Open, 2020, 3, e201323.	2.8	36
31	First Mildly III, Nonhospitalized Case of Coronavirus Disease 2019 (COVID-19) Without Viral Transmission in the United States—Maricopa County, Arizona, 2020. Clinical Infectious Diseases, 2020, 71, 807-812.	2.9	33
32	Reducing Antibiotic Use in Ambulatory Care Through Influenza Vaccination. Clinical Infectious Diseases, 2020, 71, e726-e734.	2.9	7
33	Transmission of SARS-COV-2 Infections in Households - Tennessee and Wisconsin, April-September 2020. Morbidity and Mortality Weekly Report, 2020, 69, 1631-1634.	9.0	94
34	Early Season Pediatric Influenza B/Victoria Virus Infections Associated with a Recently Emerged Virus Subclade — Louisiana, 2019. Morbidity and Mortality Weekly Report, 2020, 69, 40-43.	9.0	23
35	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak — United States, December 31, 2019–February 4, 2020. Morbidity and Mortality Weekly Report, 2020, 69, 140-146.	9.0	343
36	Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 — United States, January–February 2020. Morbidity and Mortality Weekly Report, 2020, 69, 245-246.	9.0	369

MELISSA A ROLFES

#	Article	IF	CITATIONS
37	Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020. Morbidity and Mortality Weekly Report, 2020, 69, 1631-1634.	9.0	212
38	Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET). Open Forum Infectious Diseases, 2019, 6, .	0.4	55
39	Measurement of birth outcomes in analyses of the impact of maternal influenza vaccination. Influenza and Other Respiratory Viruses, 2019, 13, 547-555.	1.5	5
40	Burden of influenza-associated respiratory hospitalizations in the Americas, 2010–2015. PLoS ONE, 2019, 14, e0221479.	1.1	34
41	Update: Influenza Activity — United States, September 30, 2018–February 2, 2019. Morbidity and Mortality Weekly Report, 2019, 68, 125-134.	9.0	61
42	Estimating Risk to Responders Exposed to Avian Influenza A H5 and H7 Viruses in Poultry, United States, 2014–2017. Emerging Infectious Diseases, 2019, 25, 1011-1014.	2.0	5
43	Effects of Influenza Vaccination in the United States During the 2017–2018 Influenza Season. Clinical Infectious Diseases, 2019, 69, 1845-1853.	2.9	218
44	Influenza Vaccine Effectiveness in the United States During the 2016–2017 Season. Clinical Infectious Diseases, 2019, 68, 1798-1806.	2.9	90
45	Update: Influenza Activity in the United States During the 2018–19 Season and Composition of the 2019–20 Influenza Vaccine. Morbidity and Mortality Weekly Report, 2019, 68, 544-551.	9.0	98
46	Notes from the Field: Assessment of State-Level Influenza Season Severity — Minnesota and Utah, 2017–18 Influenza Season. Morbidity and Mortality Weekly Report, 2019, 68, 165-166.	9.0	1
47	Estimating the Incidence of Influenza at the State Level — Utah, 2016–17 and 2017–18 Influenza Seasons. Morbidity and Mortality Weekly Report, 2019, 68, 1158-1161.	9.0	2
48	Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza and Other Respiratory Viruses, 2018, 12, 132-137.	1.5	231
49	Non-mumps Viral Parotitis During the 2014–2015 Influenza Season in the United States. Clinical Infectious Diseases, 2018, 67, 493-501.	2.9	33
50	Kinetics of Serological Responses in Critically III Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009–2011. Journal of Infectious Diseases, 2018, 217, 1078-1088.	1.9	6
51	An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine, 2018, 36, 7331-7337.	1.7	18
52	Influenza-Associated Parotitis During the 2014–2015 Influenza Season in the United States. Clinical Infectious Diseases, 2018, 67, 485-492.	2.9	8
53	Update: Influenza Activity — United States and Worldwide, May 20–October 13, 2018. Morbidity and Mortality Weekly Report, 2018, 67, 1178-1185.	9.0	15
54	Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis. Journal of Infectious Diseases, 2017, 215, 693-697.	1.9	20

MELISSA A ROLFES

#	Article	IF	CITATIONS
55	Efficacy of trivalent influenza vaccine against laboratory-confirmed influenza among young children in a randomized trial in Bangladesh. Vaccine, 2017, 35, 6967-6976.	1.7	14
56	Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts. BMC Neurology, 2017, 17, 110.	0.8	13
57	Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen Shedding. Open Forum Infectious Diseases, 2016, 3, ofv194.	0.4	18
58	Respiratory Viral Testing and Influenza Antiviral Prescriptions During Hospitalization for Acute Respiratory Illnesses. Open Forum Infectious Diseases, 2016, 3, ofv216.	0.4	11
59	Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis. Open Forum Infectious Diseases, 2015, 2, ofv157.	0.4	22
60	Epidemiology of Meningitis in an HIV-Infected Ugandan Cohort. American Journal of Tropical Medicine and Hygiene, 2015, 92, 274-279.	0.6	60
61	Early ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis and Macrophage Activation in a Multisite Randomized Trial. Journal of Infectious Diseases, 2015, 212, 769-778.	1.9	60
62	Cellular Immune Activation in Cerebrospinal Fluid From Ugandans With Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome. Journal of Infectious Diseases, 2015, 211, 1597-1606.	1.9	55
63	Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited Settings. Open Forum Infectious Diseases, 2014, 1, ofu070.	0.4	36
64	Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal Contrast. Emerging Infectious Diseases, 2014, 20, 45-53.	2.0	253
65	The Effect of Therapeutic Lumbar Punctures on Acute Mortality From Cryptococcal Meningitis. Clinical Infectious Diseases, 2014, 59, 1607-1614.	2.9	145
66	Cryptococcus neoformans Ex Vivo Capsule Size Is Associated With Intracranial Pressure and Host Immune Response in HIV-associated Cryptococcal Meningitis. Journal of Infectious Diseases, 2014, 209, 74-82.	1.9	90
67	Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. Metabolic Brain Disease, 2014, 29, 269-279.	1.4	45
68	Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis. New England Journal of Medicine, 2014, 370, 2487-2498.	13.9	387
69	Supply of neuraminidase inhibitors related to reduced influenza <scp>A</scp> ( <scp>H</scp> 1 <scp>N</scp> 1) mortality during the 2009–2010 <scp>H</scp> 1 <scp>N</scp> 1 pandemic: summary of an ecological study. Influenza and Other Respiratory Viruses, 2013, 7, 82-86.	1.5	7
70	Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis. PLoS Medicine, 2012, 9, e1001316.	3.9	79
71	Cryptococcal Genotype Influences Immunologic Response and Human Clinical Outcome after Meningitis. MBio, 2012, 3, .	1.8	79
72	Development of Clinical Immunity to Malaria in Highland Areas of Low and Unstable Transmission. American Journal of Tropical Medicine and Hygiene, 2012, 87, 806-812.	0.6	20

#	Article	IF	CITATIONS
73	Supply of Neuraminidase Inhibitors Related to Reduced Influenza A (H1N1) Mortality during the 2009–2010 H1N1 Pandemic: An Ecological Study. PLoS ONE, 2012, 7, e43491.	1.1	9
74	Detection and Stability of SARS-CoV-2 in Three Self-Collected Specimen Types: Flocked Midturbinate Swab (MTS) in Viral Transport Media, Foam MTS, and Saliva. Microbiology Spectrum, 0, , .	1.2	1